Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Gynecology

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 70 articles: HTML format

Single Articles

February 2026
1. SCHEVENHOVEN VJC, Jansen EEL, Siebers AG, de Kok IMCM, et al
   Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study.
   Eur J Cancer. 2026;237:116601.
   PubMed     Abstract available
   
   
   
2. PEDERSEN S, Colmorn LB, Ellebaek E, Kristensen SG, et al
   Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.
   Eur J Cancer. 2026;237:116584.
   PubMed     Abstract available
   
   
   January 2026
3. KASIUS JC, Kildal W, Vrede SW, Pijnenborg JMA, et al
   Response to letter Re: Surgical stage in the era of molecular profiling of endometrial cancer.
   Eur J Cancer. 2026;236:116268.
   PubMed    
   
   
   
4. NARDIN S, Bruzzone M, Arecco L, Chiappe E, et al
   Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.
   Eur J Cancer. 2026;236:116266.
   PubMed     Abstract available
   
   
   
5. TYAGI B, Toppo L, Biradar A
   Letter Re: Surgical stage in the era of molecular profiling of endometrial cancer.
   Eur J Cancer. 2026;236:116267.
   PubMed    
   
   
   
6. LEONE ROBERTI MAGGIORE U, Fanfani F, Capasso I, Perrone E, et al
   Fertility-sparing vs hysterectomy for uterine STUMP: A pragmatic clinical study.
   Eur J Cancer. 2026;236:116260.
   PubMed     Abstract available
   
   
   
7. NYBACK S, Poromaa IS, Lindman H, Hirschberg AL, et al
   Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen.
   Eur J Cancer. 2026;236:116261.
   PubMed     Abstract available
   
   
   
8. SPATA A, Ribeiro JM, Vigneri P, Zambelli A, et al
   Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
   Eur J Cancer. 2026;235:116230.
   PubMed     Abstract available
   
   
   
9. WOODFORD R, Lord S, Decaria A, Simes J, et al
   Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.
   Eur J Cancer. 2026;235:116231.
   PubMed     Abstract available
   
   
   December 2025
10. KASIUS JC, Kildal W, Vrede SW, Askautrud HA, et al
    Surgical stage in the era of molecular profiling of endometrial cancer.
    Eur J Cancer. 2025;233:116164.
    PubMed     Abstract available
    
    
    
11. LIN Y, Chen X, Chen W, Sun Y, et al
    Letter to the editor Re: Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
    Eur J Cancer. 2025;233:116163.
    PubMed    
    
    
    November 2025
12. SECCHI M, Signorelli M, Rulli E, Maruccio M, et al
    Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2025;232:116116.
    PubMed     Abstract available
    
    
    
13. PUJOL P, Roca L, Lortholary A, Lasset C, et al
    Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
    Eur J Cancer. 2025;231:116101.
    PubMed     Abstract available
    
    
    October 2025
14. LOMBAERS MS, Reijnen C, Sprik A, Bretova P, et al
    ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment.
    Eur J Cancer. 2025;231:116058.
    PubMed     Abstract available
    
    
    
15. RAMESH-KUMAR D, Sanchez-Castillo A, Soler M, Martin-Tejera JF, et al
    Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models.
    Eur J Cancer. 2025;230:116040.
    PubMed     Abstract available
    
    
    September 2025
16. LI H, Sui T, He Q
    Letter Re: ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
    Eur J Cancer. 2025;230:115803.
    PubMed    
    
    
    
17. RAMOS-CASALLAS A, Cardona-Mendoza A, Perdomo-Lara SJ, Rico-Mendoza A, et al
    Performance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis.
    Eur J Cancer. 2025;229:115768.
    PubMed     Abstract available
    
    
    August 2025
18. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
    Response to Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2- a multinational population-based cohort study.
    Eur J Cancer. 2025;228:115743.
    PubMed    
    
    
    
19. ZHANG Y, Kang Q, Qu R
    Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;228:115742.
    PubMed    
    
    
    
20. WANG L, Chang Q, Li M
    Letter Re: Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly (ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;228:115740.
    PubMed    
    
    
    
21. CAPASSO I, Perrone E, Loverro M, Giannarelli D, et al
    Focal lymphovascular space invasion: Friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas.
    Eur J Cancer. 2025;228:115736.
    PubMed     Abstract available
    
    
    
22. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    PubMed     Abstract available
    
    
    
23. PERRONE E, Distefano E, Palmieri E, Giannarelli D, et al
    ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
    Eur J Cancer. 2025;227:115686.
    PubMed     Abstract available
    
    
    July 2025
24. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
    Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;227:115664.
    PubMed     Abstract available
    
    
    
25. BLONS H, Abdelli J, Landman S, Taly V, et al
    Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.
    Eur J Cancer. 2025;225:115534.
    PubMed     Abstract available
    
    
    June 2025
26. CAPOZZI VA, Perrone E, Scarpelli E, Tarantino V, et al
    Exploring isolated tumor cells entity in endometrial cancer.
    Eur J Cancer. 2025;225:115586.
    PubMed     Abstract available
    
    
    
27. COLEMAN RL, Fleming GF, Brady MF, Swisher EM, et al
    Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
    Eur J Cancer. 2025;225:115587.
    PubMed     Abstract available
    
    
    
28. LEDERMANN JA, Oza AM, Lorusso D, Aghajanian C, et al
    Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
    Eur J Cancer. 2025;225:115584.
    PubMed     Abstract available
    
    
    May 2025
29. PORTER JM, Jin C, Churchman M, Croy I, et al
    Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer.
    Eur J Cancer. 2025;224:115522.
    PubMed     Abstract available
    
    
    
30. WANG H, Wang N
    Letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 May 19:115515. doi: 10.1016/j.ejca.2025.115515.
    PubMed    
    
    
    
31. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Corrigendum to "Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study" [Eur J Cancer 222 (2025) 115472].
    Eur J Cancer. 2025;223:115492.
    PubMed    
    
    
    
32. HOLLIS RL, Herrington CS, Gourley C
    Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025 May 5:115491. doi: 10.1016/j.ejca.2025.115491.
    PubMed    
    
    
    
33. KARABUGA B, Baskurt K, Mammadzada N, Sutcuoglu O, et al
    Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high-grade serous carcinoma.
    Eur J Cancer. 2025 May 4:115490. doi: 10.1016/j.ejca.2025.115490.
    PubMed    
    
    
    April 2025
34. FIORE M, Ljevar S, Raut CP, Personeni G, et al
    Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study.
    Eur J Cancer. 2025;222:115474.
    PubMed     Abstract available
    
    
    
35. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;222:115472.
    PubMed     Abstract available
    
    
    
36. LIU W, Yang Y
    Letter re: The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025 Apr 25:115446. doi: 10.1016/j.ejca.2025.115446.
    PubMed    
    
    
    
37. ONAL C, Elmali A, Demirhan B, Guler OC, et al
    Letter comments on: "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial".
    Eur J Cancer. 2025 Apr 22:115448. doi: 10.1016/j.ejca.2025.115448.
    PubMed    
    
    
    
38. EMINOWICZ G, Vaja S, Hackshaw A, McCormack M, et al
    Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 Apr 22:115449. doi: 10.1016/j.ejca.2025.115449.
    PubMed    
    
    
    
39. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
    Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
    Eur J Cancer. 2025;222:115438.
    PubMed     Abstract available
    
    
    
40. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
    Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
    Eur J Cancer. 2025;222:115434.
    PubMed     Abstract available
    
    
    
41. LEIBETSEDER A, Berghoff AS
    Response to letter commenting on "Association of pregnancy with tumour progression in patients with glioma".
    Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411.
    PubMed    
    
    
    
42. DANG C, Liu P, Yu X
    Letter Re: Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410.
    PubMed    
    
    
    March 2025
43. MAENG CH, Han K, Hong JY, Park JH, et al
    Association between premature menopause and the risk of biliary tract cancer: A nationwide cohort study.
    Eur J Cancer. 2025;220:115387.
    PubMed     Abstract available
    
    
    
44. EMINOWICZ G, Vaja S, Gallardo D, Kent C, et al
    Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025;220:115375.
    PubMed     Abstract available
    
    
    
45. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    PubMed     Abstract available
    
    
    
46. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    PubMed     Abstract available
    
    
    February 2025
47. VILLACAMPA G, Eminowicz G, Navarro V, Carita L, et al
    Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
    Eur J Cancer. 2025;220:115329.
    PubMed     Abstract available
    
    
    
48. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    PubMed     Abstract available
    
    
    
49. VERGOTE I, Copeland LJ, Van Gorp T, Laenen A, et al
    Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
    Eur J Cancer. 2025;219:115306.
    PubMed     Abstract available
    
    
    
50. HASEGAWA K, Nishio S, Yamamoto K, Fujiwara H, et al
    Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
    Eur J Cancer. 2025;219:115304.
    PubMed     Abstract available
    
    
    
51. HOLLIS RL, Churchman M, Grimes GR, Meynert AM, et al
    Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025;219:115299.
    PubMed     Abstract available
    
    
    January 2025
52. LI Z, Peng J, Zhang B, Zhao C, et al
    The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025;218:115258.
    PubMed     Abstract available
    
    
    
53. LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al
    Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025;218:115259.
    PubMed     Abstract available
    
    
    
54. OAKNIN A, Monk BJ, de Melo AC, Kim HS, et al
    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
    Eur J Cancer. 2025;216:115146.
    PubMed     Abstract available
    
    
    December 2024
55. MARME F, Krieghoff-Henning EI, Kiehl L, Wies C, et al
    Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
    Eur J Cancer. 2024;216:115199.
    PubMed     Abstract available
    
    
    
56. QUESADA S, Penault-Llorca F, Matias-Guiu X, Banerjee S, et al
    Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
    Eur J Cancer. 2024;215:115169.
    PubMed     Abstract available
    
    
    
57. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
    Maternal use of hormonal contraception and risk of childhood leukemia: A Scandinavian population-based cohort study.
    Eur J Cancer. 2024;215:115168.
    PubMed     Abstract available
    
    
    November 2024
58. MATIAS-GUIU X, Lax S, Raspollini MR, Palacios J, et al
    FIGO 2023 staging for endometrial cancer, when, if it is not now?
    Eur J Cancer. 2024;213:115115.
    PubMed     Abstract available
    
    
    October 2024
59. WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al
    Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
    Eur J Cancer. 2024;212:115063.
    PubMed     Abstract available
    
    
    
60. GIANNOPOULOS S, Naeem S, Nasioudis D, Gossner G, et al
    Value of surgical lymph node assessment for patients with vulvar melanoma.
    Eur J Cancer. 2024;210:114303.
    PubMed     Abstract available
    
    
    September 2024
61. BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al
    Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
    Eur J Cancer. 2024;211:114310.
    PubMed     Abstract available
    
    
    
62. VULSTEKE C, Chambers SK, Perez MJR, Chan JK, et al
    Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
    Eur J Cancer. 2024;208:114157.
    PubMed     Abstract available
    
    
    August 2024
63. BOLLINO M, Geppert B, Lonnerfors C, Masback A, et al
    Prevalence and size of pelvic sentinel lymph node metastases in endometrial cancer.
    Eur J Cancer. 2024;209:114265.
    PubMed     Abstract available
    
    
    July 2024
64. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    PubMed     Abstract available
    
    
    
65. SOUTHWORTH E, Thomson JP, Croy I, Churchman M, et al
    Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas.
    Eur J Cancer. 2024;208:114205.
    PubMed     Abstract available
    
    
    May 2024
66. ROMA C, Esposito Abate R, Sacco A, Califano D, et al
    Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Eur J Cancer. 2024;206:114127.
    PubMed     Abstract available
    
    
    April 2024
67. BOLLINO M, Geppert B, Lonnerfors C, Persson J, et al
    A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.
    Eur J Cancer. 2024;204:114049.
    PubMed     Abstract available
    
    
    
68. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
    Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913.
    Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017.
    PubMed    
    
    
    March 2024
69. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
    Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
    Eur J Cancer. 2024;203:114039.
    PubMed     Abstract available
    
    
    
70. BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al
    Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2024;202:113978.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum